Literature DB >> 31044232

Use of Routine Complete Blood Count Results to Rule Out Anaplasmosis Without the Need for Specific Diagnostic Testing.

Sarah E Turbett1,2, Melis N Anahtar1, Vikram Pattanayak1, Marwan M Azar3, K C Coffey4, George Eng1, Joseph W Rudolf5, Kent B Lewandrowski1, Jason Baron1, Eric S Rosenberg1, John A Branda1.   

Abstract

BACKGROUND: Anaplasmosis presents with fever, headache, and laboratory abnormalities including leukopenia and thrombocytopenia. Polymerase chain reaction (PCR) is the preferred diagnostic but is overutilized. We determined if routine laboratory tests could exclude anaplasmosis, improving PCR utilization.
METHODS: Anaplasma PCR results from a 3-year period, with associated complete blood count (CBC) and liver function test results, were retrospectively reviewed. PCR rejection criteria, based on white blood cell (WBC) and platelet (PLT) counts, were developed and prospectively applied in a mock stewardship program. If rejection criteria were met, a committee mock-refused PCR unless the patient was clinically unstable or immunocompromised.
RESULTS: WBC and PLT counts were the most actionable routine tests for excluding anaplasmosis. Retrospective review demonstrated that rejection criteria of WBC ≥11 000 cells/µL or PLT ≥300 000 cells/µL would have led to PCR refusal in 428 of 1685 true-negative cases (25%) and 3 of 66 true-positive cases (5%) involving clinically unstable or immunocompromised patients. In the prospective phase, 155 of 663 PCR requests (23%) met rejection criteria and were reviewed by committee, which endorsed refusal in 110 of 155 cases (71%) and approval in 45 (29%), based on clinical criteria. PCR was negative in all 45 committee-approved cases. Only 1 of 110 mock-refused requests yielded a positive PCR result; this patient was already receiving doxycycline at the time of testing.
CONCLUSIONS: A CBC-based stewardship algorithm would reduce unnecessary Anaplasma PCR testing, without missing active cases. Although the prospectively evaluated screening approach involved medical record review, this was unnecessary to prevent errors and could be replaced by a rejection comment specifying clinical situations that might warrant overriding the algorithm.
© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Anaplasma phagocytophilumzzm321990 ; PCR; diagnosis; stewardship; utilization management

Mesh:

Year:  2020        PMID: 31044232      PMCID: PMC7346887          DOI: 10.1093/cid/ciz346

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  7 in total

1.  Human granulocytic anaplasmosis in the United States from 2008 to 2012: a summary of national surveillance data.

Authors:  F Scott Dahlgren; Kristen Nichols Heitman; Naomi A Drexler; Robert F Massung; Casey Barton Behravesh
Journal:  Am J Trop Med Hyg       Date:  2015-04-13       Impact factor: 2.345

Review 2.  Clinical diagnosis and treatment of human granulocytotropic anaplasmosis.

Authors:  Johan S Bakken; J Stephen Dumler
Journal:  Ann N Y Acad Sci       Date:  2006-10       Impact factor: 5.691

3.  Clinical findings and diagnosis in human granulocytic anaplasmosis: a case series from Massachusetts.

Authors:  Ana A Weil; Elinor L Baron; Catherine M Brown; Mark S Drapkin
Journal:  Mayo Clin Proc       Date:  2012-03       Impact factor: 7.616

4.  Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis.

Authors:  J S Bakken; M E Aguero-Rosenfeld; R L Tilden; G P Wormser; H W Horowitz; J T Raffalli; M Baluch; D Riddell; J J Walls; J S Dumler
Journal:  Clin Infect Dis       Date:  2001-03-07       Impact factor: 9.079

Review 5.  Molecular diagnosis of human granulocytic anaplasmosis.

Authors:  J Stephen Dumler; Philippe Brouqui
Journal:  Expert Rev Mol Diagn       Date:  2004-07       Impact factor: 5.225

6.  Comparison of a real-time PCR method with serology and blood smear analysis for diagnosis of human anaplasmosis: importance of infection time course for optimal test utilization.

Authors:  A M Schotthoefer; J K Meece; L C Ivacic; P D Bertz; K Zhang; T Weiler; T S Uphoff; T R Fritsche
Journal:  J Clin Microbiol       Date:  2013-05-01       Impact factor: 5.948

Review 7.  Human granulocytic anaplasmosis.

Authors:  Johan S Bakken; Stephen Dumler
Journal:  Infect Dis Clin North Am       Date:  2008-09       Impact factor: 5.982

  7 in total
  1 in total

1.  Clinical Decision Support Trees Can Help Optimize Utilization of Anaplasma phagocytophilum Nucleic Acid Amplification Testing.

Authors:  Robert Hamilton; Torrie R Pandora; Jeffrey Parsonnet; Isabella W Martin
Journal:  J Clin Microbiol       Date:  2021-08-18       Impact factor: 5.948

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.